Navigation Links
Enzyme's newly discovered role may make it target for arthritis treatment

Scientists have found a new role for a previously identified enzyme that may make it a target for anti-inflammatory treatments.

The finding by researchers at Washington University School of Medicine in St. Louis shows that an enzyme known as cathepsin G regulates the ability of immune cells known as neutrophils to secrete chemicals that attract other immune cells and start the local inflammatory process. Over time, the excessive accumulation of immune cells can lead to tissue and cartilage damage in joints, causing pain and limiting mobility.

"Cathepsin G affects a very early step in this kind of immune response, so inhibiting it has attractive potential for developers of therapeutics," says senior author Christine T.N. Pham, M.D., assistant professor of medicine and a rheumatologist at Barnes-Jewish Hospital.

The study appears in the June 2005 issue of Immunity.

Cathepsin G, which is made by the neutrophils it regulates, is also an attractive target because it belongs to a class of enzymes known as proteases. One principal type of treatment for HIV, the virus that causes AIDS, inhibits proteases, so scientists who try to block cathepsin G's role in inflammation will already have an extensive body of research results to refer to.

Pham's lab uses mouse models of arthritis to study the contributions of proteases and other factors to inflammation and arthritis. One such model involves injecting mice with collagen from calf joints.

"The mice make antibodies to that protein because it's somewhat foreign, but the antibodies have enough cross-reactivity that they will bind to the mouse's own cartilage and collagen and initiate an inflammation," Pham explains. "This leads to a condition similar to rheumatoid arthritis in the mice."

Three years ago, Pham's lab published results showing that mice deficient in cathepsin G and other closely related proteases failed to develop arthritis after the injections. This led them to look for the mechanisms by which these proteases regulate inflammation.

Observations made by Pham's lab and other groups had linked the earliest stages of inflammation in the animal models to neutrophils, which are a kind of immune system firestarter. They arrive first at sites of injury, infection or irritation and secrete chemicals that bring in secondary waves of other immune attack cells.

"The contributions of the neutrophil weren't always appreciated by scientists," Pham notes. "When patients come to their doctors with arthritis symptoms, the inflammation typically is so well-established that neutrophils are no longer the predominant cell type."

Animal models of inflammation let scientists watch all stages of the inflammatory process and allowed them to see how important neutrophils are to the early stages of that process.

In the new study, Pham and her colleagues showed that cathepsin G is secreted by neutrophils, binds to the cells' surface membranes, and affects the rearrangement of integrins, an important group of adhesion compounds on the surface of neutrophils.

"The way these integrins rearrange and cluster on the cell surface can send a signal back into the cell that modifies the cell's behavior, allowing it to do things like secrete inflammatory factors," Pham explains. "The proteases' ability to affect integrin rearrangement is dependent on their catalytic activity, and that's an ability that can be taken away from them."

Pham suspects this class of proteases may also be making significant contributions to other autoimmune and inflammatory conditions besides arthritis. She plans further studies to investigate this possibility. Her lab is also working to determine what molecules cathepsin G is sticking to and interacting with on the surfaces of neutrophils and other cells.

###

Raptis SZ, Shapiro SD, Simmons PM, Cheng AM, Pham CTN. Serine protease Cathepsin G regulates adhesion-dependent ne utrophil effector functions by modulation integrin clustering. Immunity, June 7, 2005, 679-691. Funding from the Arthritis Foundation and the National Institutes of Health supported this research.


'"/>

Source:Washington University School of Medicine


Related biology news :

1. U of M researcher examines newly emerging deadly disease
2. Most common lung cancers may begin in newly discovered cells
3. Shorter colds, milder flu may follow from newly revealed immune mechanism
4. Faults in newly discovered breast stem cells may lead to tumours
5. Hepatitis C therapy: Inhibiting newly discovered microDNA molecule
6. Drug discovery team to explore newly discovered deep-sea reefs
7. Study shows enzyme builds neurotransmitters via newly discovered pathway
8. Newly-discovered class of genes determines ?and restricts ?stem cell fate
9. Newly discovered virus linked to childhood lung disorders and Kawasaki disease
10. New protein discovered by Hebrew University researchers
11. New RNA polymerase discovered in plants
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/15/2016)... New York , March 15, 2016 ... new market report published by Transparency Market Research "Digital Door ... Trends and Forecast 2015 - 2023," the global digital door ... US$ 731.9 Mn in 2014 and is forecast to grow ... 2023. Growth of micro, small and medium enterprises (MSMEs) across ...
(Date:3/11/2016)... http://www.apimages.com ) - --> http://www.apimages.com ) - ... Images ( http://www.apimages.com ) - Germany . ... new refugee identity cards. DERMALOG will be unveiling this device, and ... Hanover next week.   --> Germany ... the new refugee identity cards. DERMALOG will be unveiling this device, ...
(Date:3/9/2016)... March 9, 2016 This BCC Research report ... of the RNA Sequencing (RNA Seq) market for the ... instruments, tools and reagents, data analysis, and services. ... of the RNA-Sequencing market such as RNA-Sequencing tools and ... main factors affecting each segment and forecast their market ...
Breaking Biology News(10 mins):
(Date:5/5/2016)... ... May 05, 2016 , ... ... identification of its first three targets, it has identified a fourth in a ... implicated in the development and progression of Alzheimer’s disease (AD). , ...
(Date:5/4/2016)... N.J. , May 4, 2016  Bayer ... its oncology compound Stivarga ® (regorafenib) tablets ... carcinoma (HCC) has met its primary endpoint of ... study, called RESORCE, evaluated the efficacy and safety ... has progressed after treatment with sorafenib. The safety ...
(Date:5/4/2016)... ... 04, 2016 , ... Nutrafol®, a first-to-market smart-supplement for healthy ... stress related hair loss. With patent-pending formulas for both female hair loss and ... the medical and salon channels nationwide. , Dermatologists, Plastic Surgeons and hair ...
(Date:5/3/2016)... ... 03, 2016 , ... Leading CEOs from biotech, pharmaceutical, and ... June 1st at The Four Seasons Hotel Boston. , The Boston CEO Conference ... exclusive access to key decision makers who influence deal making and investment. Attendees ...
Breaking Biology Technology: